How Long Has Retatrutide Been Around? History Since 2016

How long has retatrutide been around?

About ten years. Retatrutide (LY3437943, often shortened to “reta”) was designed in Eli Lilly’s peptide laboratories around 2016-2018, first given to humans in 2019, published in Phase 2 in 2023, and completed its five pivotal Phase 3 trials between December 2025 and July 2026. It is still investigational; Lilly says it plans to file for approval no later than the first quarter of 2027.

Overview

Retatrutide (LY3437943) is one of the most significant metabolic drug programs of recent years. Its path from Eli Lilly’s peptide research labs to a Phase 3 investigational compound shows how incretin-based drugs have moved from single-target to multi-target designs.

Preclinical Discovery (2016-2019)

Concept and Rationale

Retatrutide grew out of Eli Lilly’s long experience in incretin biology, built over more than two decades of research that also produced tirzepatide (Mounjaro/Zepbound). Lilly researchers, led by Tamer Coskun and colleagues in the diabetes and obesity research division, saw that the incretin field was coming round to a key idea: one molecule acting on several metabolic hormone receptors could do more than single-receptor agonists, with the effects reinforcing each other.

The specific rationale for adding glucagon receptor agonism to the GIP/GLP-1 dual agonist framework was grounded in preclinical evidence that glucagon promotes energy expenditure and hepatic lipid oxidation. While this concept had been explored by academic groups and other pharmaceutical companies, Eli Lilly was well placed to carry it out, given its experience engineering multi-receptor peptides.

Peptide Engineering

The discovery phase involved extensive structure-activity relationship (SAR) studies to design a single peptide capable of activating GIP, GLP-1, and glucagon receptors with appropriate potency ratios. Starting from a GIP-based peptide backbone, Lilly chemists systematically modified amino acid residues to broaden receptor specificity while maintaining favorable pharmacokinetic properties. The addition of a C20 fatty diacid moiety via a gamma-glutamic acid linker provided albumin binding for half-life extension.

Multiple candidate molecules were synthesized and screened in cell-based receptor activation assays and animal models before LY3437943 was selected as the development candidate based on its optimal balance of receptor potencies, metabolic effects, and pharmacokinetic profile.

Preclinical Pharmacology

Extensive preclinical studies in diet-induced obese mice, diabetic mouse models, and non-human primates established the pharmacological proof of concept. Key preclinical findings included:

• Dose-dependent weight loss exceeding that of single- or dual-receptor agonists
• Improved glucose tolerance and insulin sensitivity
• Increased energy expenditure attributable to the glucagon receptor component
• Reduced hepatic steatosis
• Acceptable preclinical safety and toxicology profile

These data supported an Investigational New Drug (IND) application to the FDA, enabling the transition to human clinical testing.

Phase 1: First-in-Human (2019-2021)

Study Design

Phase 1 began with a single ascending dose (SAD) study in healthy adult volunteers (NCT03841630, Singapore, 2019), followed by a separate randomized, double-blind, placebo-controlled multiple ascending dose (MAD) trial in patients with type 2 diabetes (NCT04143802, December 2019 to December 2020). Together they characterized safety, tolerability, and pharmacokinetics across a range of dose levels.

Key Phase 1 Findings

• Safety: Retatrutide was generally well tolerated. Gastrointestinal adverse events (nausea, vomiting, diarrhea) were the most common side effects, consistent with the known pharmacology of GLP-1R agonism.
• Pharmacokinetics: The half-life was determined to be approximately six days, supporting once-weekly dosing. Dose-proportional increases in drug exposure were observed.
• Pharmacodynamic signals: Even at early dose levels, reductions in blood glucose and preliminary evidence of weight loss were observed, providing early biological proof of concept.
• Dose selection: Phase 1 data informed the dose range (0.5-12 mg) and escalation schedules used in the subsequent Phase 2 program.

The Phase 1 results were included in the detailed pharmacology paper by Coskun et al. (2022) in Cell Metabolism, which presented both preclinical and Phase 1 clinical data in an integrated analysis.

Phase 2: Proof of Efficacy (2021-2023)

Trial Design and Execution

Two Phase 2 trials began in 2021 and were the most important milestone in retatrutide’s development:

Phase 2 Obesity Trial (NCT04881760): A 48-week, randomized, double-blind, placebo-controlled, dose-ranging study in 338 adults with obesity or overweight. Participants were randomized to placebo or one of six retatrutide groups: 1 mg; 4 mg starting at 2 mg or at 4 mg; 8 mg starting at 2 mg or at 4 mg; and 12 mg starting at 2 mg.

Phase 2 Type 2 Diabetes Trial (NCT04867785): A 36-week, randomized, double-blind, placebo- and active-comparator-controlled study in 281 adults with type 2 diabetes. Participants were randomized to placebo, dulaglutide 1.5 mg (active comparator), or one of six retatrutide groups (0.5 mg; 4 mg with or without escalation; 8 mg starting at 2 mg or at 4 mg; 12 mg).

Landmark Results

The Phase 2 results, presented at the American Diabetes Association (ADA) Scientific Sessions in June 2023 and published at the same time in the New England Journal of Medicine and The Lancet, were striking:

• Weight loss: Up to 24.2% mean weight reduction at 48 weeks in the obesity trial (12 mg group), the highest ever reported for a pharmaceutical agent
• Glycemic control: Up to 2.02% HbA1c reduction in the diabetes trial, with most participants at higher doses achieving non-diabetic HbA1c levels
• Liver fat: Up to ~82% relative reduction in liver fat content
• Tolerability: GI adverse event profile consistent with the incretin class; manageable with dose escalation

Scientific and Media Impact

The Phase 2 results drew a great deal of attention from scientists and the mainstream media. The magnitude of weight loss, in particular, was widely noted as approaching bariatric surgery outcomes, prompting discussion about the potential for pharmacotherapy to serve as an alternative or complement to surgical intervention for severe obesity.

Phase 3: The TRIUMPH Program (2023-Present)

Program Design

After the strong Phase 2 results, Eli Lilly moved retatrutide into Phase 3 under the TRIUMPH name. The TRIUMPH program comprises multiple pivotal trials designed to provide the definitive efficacy and safety data required for regulatory submissions.

TRIUMPH-1 (Obesity)

TRIUMPH-1 is the pivotal obesity trial, evaluating retatrutide in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities and without diabetes. It enrolled 2,339 participants and reported topline results on May 21, 2026: -28.3% mean weight loss at 12 mg over 80 weeks. The paper was published in the New England Journal of Medicine on September 29, 2026. See TRIUMPH-1.

TRIUMPH-2 (Obesity with Type 2 Diabetes)

TRIUMPH-2 evaluated retatrutide in 1,152 adults with obesity or overweight and type 2 diabetes, with a nested obstructive sleep apnea (OSA) basket. It reported on July 23, 2026 (-20.8% weight loss at 12 mg over 80 weeks) and was published in The Lancet on September 29, 2026. See TRIUMPH-2. The TRANSCEND program is the dedicated type 2 diabetes development pathway.

Additional Trials

The program also includes TRIUMPH-3 (severe obesity with cardiovascular disease, reported July 23, 2026), TRIUMPH-4 (obesity with knee osteoarthritis, reported December 2025), TRIUMPH-5 (head-to-head against tirzepatide, still running) and the TRIUMPH-Outcomes cardiovascular trial. MASLD/MASH is studied separately in the SYNERGY and MACELD trials.

Key Milestones Timeline

Eli Lilly’s Strategic Context

Retatrutide’s development occurs within Eli Lilly’s broader metabolic disease portfolio, which also includes tirzepatide (approved as Mounjaro for type 2 diabetes and Zepbound for obesity) and orforglipron (Foundayo, an oral GLP-1R agonist approved by the FDA on April 1, 2026). This portfolio reflects Lilly’s strategy of pursuing multiple complementary approaches to metabolic disease:

• Tirzepatide: Dual GIP/GLP-1 agonist (approved, injectable)
• Retatrutide: Triple GIP/GLP-1/glucagon agonist (Phase 3, injectable)
• Orforglipron (Foundayo): Oral GLP-1R agonist (approved, oral)

If retatrutide is approved, it could be positioned as a more potent option for patients requiring greater weight loss or those with MASLD, while tirzepatide and orforglipron serve other patient segments. This tiered approach would give doctors a range of options to match different patients.

Challenges and Considerations

Manufacturing

Producing complex peptide therapeutics at scale is a significant manufacturing challenge. Eli Lilly has invested billions of dollars in manufacturing capacity expansion to support its metabolic portfolio, and retatrutide production capacity will be a factor in the drug’s commercial launch, if approved.

Market Competition

The metabolic drug market is intensely competitive. By the time retatrutide potentially reaches the market, several other incretin-based agents will be available, including next-generation candidates from competitors like Novo Nordisk, Amgen, and others. Retatrutide will need to demonstrate differentiated value, whether through superior efficacy, unique hepatic effects, or other clinical advantages, to carve out a distinct market position.

Regulatory Considerations

The regulatory pathway for retatrutide involves demonstrating efficacy and safety in large Phase 3 trials for each proposed indication. The FDA’s requirements for obesity drugs include demonstration of clinically meaningful weight loss versus placebo, an acceptable safety profile, and sufficient long-term data. Additional regulatory pathways for potential MASLD indications would require separate clinical programs.

Summary

Retatrutide’s history runs from rational drug design through preclinical testing and early clinical proof of concept to large pivotal trials. Each phase has strengthened the idea that triple receptor agonism brings bigger metabolic benefits than simpler single- or dual-receptor drugs. The pivotal TRIUMPH and TRANSCEND-T2D-1 trials have now reported; the marketing application and the FDA’s review are the next steps in determining whether retatrutide’s promise will translate into regulatory approval and clinical practice.